Dementia is not a single disease, but rather a term that describes a group of symptoms affecting memory, thinking, and social abilities severely enough to interfere with daily life. While there is currently no cure for dementia, various treatment approaches aim to slow disease progression, manage symptoms, and improve the quality of life for people living with this condition and their families.

Managing Life with Dementia: What Treatment Can Achieve

When someone receives a diagnosis of dementia, whether it’s Alzheimer’s disease, vascular dementia, or another form, the focus of treatment shifts toward maintaining function and comfort for as long as possible. Treatment goals center on preserving independence, managing behavioral changes, and supporting both the person with dementia and their caregivers through the progression of the disease. The approach to care depends heavily on the type of dementia, the stage of the illness, and individual patient characteristics such as age, overall health, and personal circumstances.^[1][2]

Medical professionals recognize that dementia affects millions worldwide—over 55 million people globally as of 2021, with nearly 10 million new cases each year.^[4] This makes it the seventh leading cause of death and a major cause of disability among older adults. Because dementia is progressive, meaning it worsens over time, treatment strategies must adapt as the disease advances. Early intervention can make a significant difference, helping individuals and families plan for the future and access therapies that may temporarily slow cognitive decline.^[2]

Current medical guidelines recommend a combination of pharmacological treatments—medications that target brain chemistry—and non-pharmacological approaches such as cognitive stimulation, lifestyle modifications, and supportive care. Researchers are also actively investigating new therapies in clinical trials, offering hope that more effective treatments may become available in the coming years.^[13][14]

Standard Medical Treatment for Dementia

Most medications available for dementia are designed to treat Alzheimer’s disease, the most common form of dementia, accounting for 60 to 80 percent of all cases. However, some of these drugs have shown benefits for other types of dementia as well, including dementia with Lewy bodies and vascular dementia.^[1][11]

Acetylcholinesterase Inhibitors

The first category of drugs commonly prescribed includes acetylcholinesterase inhibitors. These medications work by preventing an enzyme from breaking down a chemical messenger in the brain called acetylcholine, which helps nerve cells communicate with each other. When acetylcholine levels are maintained at higher levels, memory and thinking abilities may temporarily improve or stabilize.^[11][14]

Three main drugs fall into this category: donepezil (also known by the brand name Aricept), rivastigmine (Exelon), and galantamine (Reminyl). Donepezil is used for mild to moderate Alzheimer’s disease, but it is also approved for more severe cases. Rivastigmine and galantamine are typically prescribed for mild to moderate symptoms. Clinical studies suggest these medications can also help people with dementia with Lewy bodies, Parkinson’s disease dementia, and mixed dementia—a condition where someone has more than one type of dementia at the same time.^[11][15]

Side effects of acetylcholinesterase inhibitors are generally mild and often temporary. The most common include nausea and loss of appetite, which usually improve after the first two weeks of treatment. Healthcare providers typically start patients on a low dose and gradually increase it to minimize discomfort.^[11]

NMDA Receptor Antagonists

Another medication used for moderate to severe dementia is memantine, sold under brand names such as Ebixa, Marixino, or Valios. Memantine works differently than acetylcholinesterase inhibitors. It blocks the effects of excessive amounts of a chemical called glutamate in the brain. When glutamate levels are too high, they can damage nerve cells. By regulating glutamate activity, memantine may help protect brain cells and improve symptoms.^[11][14]

Memantine is prescribed for people with moderate or severe Alzheimer’s disease, dementia with Lewy bodies, and those with a combination of Alzheimer’s and vascular dementia. It is suitable for individuals who cannot take acetylcholinesterase inhibitors or who do not tolerate them well. Side effects can include headaches, dizziness, and constipation, but these are usually short-lived.^[11]

Medications for Related Conditions

Many people with dementia also have other health conditions that can worsen symptoms, particularly in vascular dementia. These include high blood pressure, heart disease, diabetes, high cholesterol, and chronic kidney disease. Treating these underlying conditions is an important part of managing dementia symptoms and slowing progression. Medications for these conditions—such as blood pressure drugs, cholesterol-lowering statins, and diabetes medications—are prescribed as part of a comprehensive treatment plan.^[11]

Depression is also common among people with dementia and may be treated with antidepressants if it appears to be an underlying cause of anxiety or mood changes.^[11]

Managing Behavioral Symptoms

In the later stages of dementia, many people develop what are called behavioral and psychological symptoms of dementia, or BPSD. These can include increased agitation, anxiety, wandering, aggression, delusions (false beliefs), and hallucinations (seeing or hearing things that aren’t there). These changes in behavior can be extremely distressing for both the person with dementia and their caregivers.^[11]

When non-drug coping strategies such as creating a calm environment, maintaining routines, and providing reassurance do not work, doctors may prescribe antipsychotic medications such as risperidone or haloperidol. These drugs are used only when there is persistent aggression or extreme distress, and when there is a risk of harm to the person or others. They are licensed specifically for moderate to severe Alzheimer’s disease and vascular dementia, and they must be used at the lowest effective dose for the shortest time possible. Regular reviews—at least every six weeks—are essential to ensure the medication is still needed and to monitor for side effects.^[11]

Non-Pharmacological Treatments

Medications are only one part of dementia care. Non-drug treatments are equally important and often form the foundation of a comprehensive care plan. These approaches focus on maintaining cognitive function, supporting independence, and enhancing quality of life.^[11][15]

Cognitive stimulation therapy, or CST, involves group activities and exercises designed to improve memory, problem-solving skills, and language abilities. Research has shown that CST benefits people with mild to moderate dementia, helping them stay mentally engaged and socially connected.^[11]

Cognitive rehabilitation is another technique where a person works with a trained professional, such as an occupational therapist, along with a family member or friend, to achieve a personal goal. This might include learning to use a mobile phone, managing daily tasks, or adapting to changes in their abilities.^[11]

Other supportive interventions include physical activity programs, music therapy, art activities, and reminiscence therapy—where people are encouraged to talk about past experiences and memories. These activities can improve mood, reduce anxiety, and provide a sense of purpose and enjoyment.^[15]

Innovative Therapies in Clinical Trials

While current medications can provide some benefit, they do not address the underlying biological causes of dementia. For this reason, researchers around the world are working to develop new treatments that could slow or even halt the progression of the disease. Clinical trials are the primary way these experimental therapies are tested for safety and effectiveness before they can be approved for widespread use.^[13][14]

Amyloid-Targeting Therapies

One of the hallmarks of Alzheimer’s disease is the buildup of abnormal proteins in the brain, including amyloid plaques and tau tangles. These protein deposits are thought to damage nerve cells and disrupt communication between them. In recent years, several new drugs have been developed that target these proteins directly.^[8][13]

Two medications that received approval from the U.S. Food and Drug Administration (FDA) are lecanemab (brand name Leqembi) and donanemab (brand name Kisunla). Both drugs are monoclonal antibodies—laboratory-made proteins that bind to amyloid plaques in the brain and help the immune system clear them away. These treatments are approved specifically for people with early Alzheimer’s disease, meaning those in the mild cognitive impairment stage or the early dementia stage who have confirmed amyloid buildup in their brains.^[13]

Clinical trials of lecanemab showed that it could slow cognitive decline by addressing the underlying biology of Alzheimer’s. Similarly, donanemab demonstrated positive results in reducing amyloid plaques and slowing the progression of symptoms in trial participants. However, these drugs are not cures, and they work only in people who have amyloid deposits. Patients must undergo diagnostic testing, such as a PET scan or spinal fluid analysis, to confirm the presence of amyloid before starting treatment.^[13]

Another drug in this category, aducanumab, was initially approved but has since been discontinued by the manufacturer. This highlights the ongoing challenges in developing effective therapies for dementia.^[13]

Trial Phases and What They Mean

Clinical trials for dementia treatments typically proceed through three main phases. Phase I trials focus on safety, testing a new drug in a small number of healthy volunteers or patients to determine if it is safe to use and what dosage is appropriate. Phase II trials involve more participants and aim to evaluate whether the drug is effective and to gather more information about side effects. Phase III trials are large-scale studies that compare the new treatment to standard care or a placebo to confirm its effectiveness and monitor for rare side effects.^[14]

Participation in clinical trials is open to people who meet specific eligibility criteria, which often include the type and stage of dementia, age, and overall health. Trials are conducted in many locations, including the United States, Europe, and other regions. They offer participants access to cutting-edge therapies that are not yet available to the general public.^[13]

Other Promising Approaches

Beyond amyloid-targeting drugs, researchers are exploring other innovative strategies. Some studies are investigating therapies that target tau protein, inflammation in the brain, or blood vessel damage. Others are looking at gene therapy approaches, which aim to correct genetic mutations that increase the risk of dementia, or immunotherapy, which uses the body’s immune system to fight disease.^[14]

Preliminary results from some trials have shown improvements in clinical parameters such as memory scores, reductions in specific symptoms, and positive safety profiles. However, many of these therapies are still in early stages of development and require further research before they can be approved for clinical use.^[14]

Coverage and Access

Access to new dementia treatments approved by regulatory agencies may depend on insurance coverage policies. In the United States, the Centers for Medicare and Medicaid Services (CMS) has released details about coverage for FDA-approved drugs such as lecanemab. Understanding these policies is important for people living with Alzheimer’s disease and their families as they consider treatment options.^[13]

Most common treatment methods

• Acetylcholinesterase inhibitors
  • Donepezil (Aricept) for mild to severe Alzheimer’s disease
  • Rivastigmine (Exelon) for mild to moderate symptoms, also used in dementia with Lewy bodies
  • Galantamine (Reminyl) for mild to moderate Alzheimer’s disease
  • Work by preventing breakdown of acetylcholine to help nerve cells communicate
  • Common side effects include nausea and loss of appetite, usually temporary
• NMDA receptor antagonists
  • Memantine (Ebixa, Marixino, Valios) for moderate to severe dementia
  • Blocks excessive glutamate to protect brain cells
  • Used in Alzheimer’s disease, dementia with Lewy bodies, and mixed dementia
  • Side effects may include headaches, dizziness, and constipation
• Antipsychotic medications
  • Risperidone and haloperidol for severe behavioral symptoms
  • Used only when there is persistent aggression or extreme distress
  • Prescribed at lowest dose for shortest time with regular reviews
  • Licensed for moderate to severe Alzheimer’s and vascular dementia
• Amyloid-targeting therapies
  • Lecanemab (Leqembi) for early Alzheimer’s disease with confirmed amyloid
  • Donanemab (Kisunla) for early Alzheimer’s disease with confirmed amyloid
  • Monoclonal antibodies that help clear amyloid plaques from the brain
  • Require diagnostic testing such as PET scan or spinal fluid analysis
  • Slow cognitive decline by addressing underlying disease biology
• Cognitive stimulation therapy
  • Group activities and exercises to improve memory, problem-solving, and language
  • Benefits people with mild to moderate dementia
  • Helps maintain mental engagement and social connections
• Cognitive rehabilitation
  • Work with trained professionals to achieve personal goals
  • May include learning to use technology or adapting daily tasks
  • Involves family members or friends in the process
• Supportive interventions
  • Physical activity programs to maintain health and mobility
  • Music therapy and art activities to improve mood
  • Reminiscence therapy to encourage discussion of memories
  • Reduce anxiety and provide sense of purpose
• Treatment of related conditions
  • Management of high blood pressure, heart disease, and diabetes
  • Cholesterol-lowering medications
  • Treatment of depression with antidepressants if appropriate
  • Important for slowing progression, especially in vascular dementia